Asset Publisher

Draft Provider-Administered Oncology Policies

To ensure that the development of medical policies occurs through an open, collaborative process, we welcome comments about medical policies that are in the draft stage. Our current draft policies are listed below.

Participating providers are invited to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration. We accept comments for 45 days from the posting date listed on the draft policy document.

Note: Coverage is subject to member's specific benefits. Group-specific policies will supersede these policies when applicable. Please refer to member's benefit plan.

How to Submit Comments on Draft Medical Policies

Participating providers can comment on draft policies using one of the following methods:

  • Send comments by mail or fax to:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202

Fax: 205-220-0878

Policy # Policy Title Print View
VP-007 Pemetrexed: Alimta®; Pemfexy™; Pemetrexed Ψ (Intravenous)
VP-209 Keytruda® (pembrolizumab) (Intravenous)
VP-256 Onivyde® (irinotecan liposome injection) (Intravenous)
VP-314 Vyxeos® (daunorubicin and cytarabine – liposome) (Intravenous)
VP-367 Elitek® (rasburicase) (Intravenous)
VP-599 Jemperli® (dostarlimab-gxly) (Intravenous)
VP-676 Rolvedon™ (eflapegrastim-xnst) (Subcutaneous)
VP-710 Epkinly™ (epcoritamab-bysp) (Subcutaneous)
VP-711 Columvi™ (glofitamab-gxbm) (Intravenous)